- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01606215
Stem Cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current treatments for MS target the immune system and are not curative. There is much interest in MSCs as they have the potential to not only affect the immune system but may also promote repair. This study will use MSCs that are harvested from the bone marrow and grown for up to 52 days before being given back to the person from whom they were harvested. This avoids any chemotherapy so is therefore safer than other types of stem cells. In this crossover study, everyone will receive their own stem cells back but in half of the patients it will be delayed by 24 weeks.
The primary outcomes are to check that the procedure is safe and to measure any changes on the MRI at 24 weeks. Other more exploratory measures will try to assess effects on repair in the central nervous system (CNS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12 0NN
- Imperial College Healthcare NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with clinically and radiologically active multiple sclerosis as defined by:
Diagnosis of MS:
- Relapsing remitting MS (RRMS): ≥ 1 moderate-severe relapse and ≥1 GEL in past 18 months or ≥ 1 moderate-severe relapse and ≥1 new T2 lesion in past 18 months.
- Secondary progressive MS (SPMS) with an increase of ≥ 1 EDSS point (if baseline EDSS ≤ 5) or 0.5 EDSS point (if baseline EDSS ≥ 5.5), in the previous 18 months and ≥ 1 GEL in past 18 months or ≥ 1 moderate-severe relapse and ≥1 new T2 lesion in past 18 months.
- Primary progressive MS (PPMS) patients with positive oligoclonal bands (OCBs) in the cerebrospinal fluid (CSF) and an increase of ≥ 1 EDSS point (if baseline EDSS is ≤ 5.0) or 0.5 EDSS point (if baseline EDSS is ≥ 5.5), or quantifiable, objective evidence of equivalent progression in the previous 18 months and ≥ 1 GEL in past 18 months or ≥ 1 new T2 lesion in past 18 months.
- Age 18 to 50 years.
- Disease duration 2 to 10 years from diagnosis (inclusive).
- Expanded Disability Status Scale (EDSS) 2.0 to 6.5 at screening evaluation.
- ≥ 1 GEL on MRI within 6 months prior to harvesting.
- Adequate culture of a subject's MSCs and their release for clinical use.
Exclusion Criteria:
- RRMS without at least one severe relapse in the previous 18 months or without at least one GEL or one new T2 in the previous 18 months.
- SPMS without relapses and without new lesions (GEL or T2 positive) at MRI in the last 18 months.
- PPMS without positive CSF OCBs or without a GEL or new T2 lesion in the previous 18 months.
- No gadolinium enhancing lesion(s) in the 3 months prior to bone marrow harvesting.
- A previously ineligible patient who failed to meet the MRI requirements of the inclusion criteria will not be reviewed again even if further imaging, revealing ≥ 1 GEL, becomes available.
- Failure of bone marrow (BM) sample to generate MSCs suitable for clinical use within a specified time frame (4 weeks).
- Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the last 3 months.
- Treatment with interferon-beta or glatiramer acetate within the last 1 month.
- Treatment with alemtuzumab (campath-1H) within the last 2 years.
- Prior treatment with total lymphoid irradiation and autologous or allogeneic hematopoietic stem cell transplantation.
- Participation in clinical trials of any experimental drugs in the 6 months before study entry.
- Corticosteroid treatment in the last 30 days.
- Presence of any active or chronic infection.
- Previous history of a malignancy other than basal cell carcinoma of the skin and carcinoma in situ that has been in remission for more than one year.
- Severely limited life expectancy by any other co-morbid illness.
- Abnormal blood counts, a history of myelodysplasia or other cytopenia.
- Known pregnancy, positive urine pregnancy test at screening or risk or pregnancy (this includes patients who are unwilling to practice active contraception during the duration of the study).
- Contraindication to MRI including but not limited to intracranial aneurysm clips (except Sugita), history of intra-orbital metal fragments that have not been removed by an MD (as confirmed by orbital X-Ray), pacemaker and non-MRI compatible devices (e.g. heart valves, inner ear implants), history of claustrophobia or the inability of the subject to lie still on their back for a period of 1.5 hours in the MRI scanner.
- An estimated glomerular filtration rate (eGFR)< 60 mL/min/1.73m2 or history or presence of renal impairment (e.g. serum creatinine clearance less than 30ml/min).
- Inability to give written informed consent/comply with study procedures.
- Any significant organ dysfunction or co-morbidity that the Investigators consider would put the subject at unacceptable risk by participating in the study or that would interfere with the functional assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mesenchymal stem cells
1-2 x106 MSCs/kg administered at Week 0
|
1.0-2.0 million cells/kg body weight
Other Names:
|
Sham Comparator: Placebo
Suspension media administered at Week 0
|
Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0
Time Frame: Up to 1 year from baseline
|
The number,time-frame and severity of adverse events in the stem cell treatment group will be compared to the placebo group.
|
Up to 1 year from baseline
|
Total number of GELs at weeks 4, 12 and 24 after MSC therapy
Time Frame: Up to 1 year from baseline
|
To evaluate the efficacy of autologous mesenchymal stem cells in MS patients, quantified by the reduction in the number of new contrast-enhancing lesions on MRI scans over 24 weeks and the total number of GEL counted over months 1, 3 and 6 will be compared between treatment groups.
|
Up to 1 year from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.
Time Frame: Months 1, 3 and 6
|
Number of contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.
|
Months 1, 3 and 6
|
Comparison of contrast enhancing lesions between treatment periods
Time Frame: Months 1-12
|
The number of contrast enhancing lesions counted over months 7, 9 and 12 (cross-over re-treatment) compared between treatment periods (placebo vs. active treatment) for each patient.
|
Months 1-12
|
Combined unique MRI activity
Time Frame: Months 1-12
|
The number of new or enlarging T2, or enhancing or re-enhancing lesions.
|
Months 1-12
|
Relapses
Time Frame: 20 months
|
number of relapses in MSC treatment group vs. placebo group in the first 6 months and after cross-over re-treatment in the two groups
|
20 months
|
Progression of disability
Time Frame: 36 months
|
time to sustained progression of disability and proportion of progression-free patients.
|
36 months
|
Disease free patients
Time Frame: 36 months
|
The proportion of disease-free patients (i.e.
patients without relapses) and progression of MRI activity in the two groups.
|
36 months
|
MSFC score
Time Frame: 36 months
|
the changes in the Multiple Sclerosis Functional Composite (MSFC) score in MSC treatment group compared to the placebo group.
|
36 months
|
peripheral immune responses
Time Frame: 48 weeks
|
changes in immune cell frequencies and serum cytokines after MSCs
|
48 weeks
|
Type 4 hypersensitivity reaction
Time Frame: 48 weeks
|
The effect of mesenchymal stem cells on delayed type hypersensitivity (Type 4 hypersensitivity reaction) as measured by the Mantoux test
|
48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paolo A Muraro, MD PhD, Imperial College London
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRO1959
- 13HH0228 (Other Identifier: Imperial College)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States